Video: B-roll - First Health Canada Approved Medical Cannabis Clinical Trial Starts Patient Recruitment
Landmark trial will be first to study safety and efficacy of a series of
SASKATOON, June 23, 2015 /CNW/ - Prairie Plant Systems and CanniMed, Canada's most well-established and reliable producer of medical
cannabis, along with researchers at McGill University Health Centre and
Dalhousie Universities, officially start patient engagement today on
the CAPRI Trial (Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of
the Knee), a randomized, double blind, placebo controlled,
proof-of-concept, crossover clinical trial of single dose vaporized
cannabis in adults with painful osteoarthritis of the knee.
Not only was this clinical trial the first to be registered with Health
Canada after the transition to the new Marihuana for Medical Purposes Regulations (MMPR), CAPRI will seek to understand the analgesic dose-response of
several varieties of medical cannabis, consisting of varying
concentrations of the two most common active ingredients:
delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). It will also
explore the short-term safety of vaporized cannabis as well as look at
functional changes and patient preference.
"Anecdotal evidence supporting cannabis as a medicine is increasing,
however this isn't quite good enough for our patients," said Brent
Zettl, President and CEO of Prairie Plant Systems Inc. and CanniMed
Ltd. "In order for medical cannabis to become a true medicine, it
requires carefully conducted trials to provide hard data. It is our
ongoing mission to support patients and their prescribing physicians
with more research into the safety and efficacy of these cannabis based
products to ensure predictable and standardized treatment options in
the near future."
The CAPRI Trial will be recruiting 40 patients suffering from serious
osteoarthritis of the knee over the two trial sites in Montreal, QC and
Halifax, NS. Patient recruitment starts today at the McGill University
Health Centre, and Dalhousie University will begin to recruit patients
"This clinical trial significantly advances medical cannabis research in
Canada," said Dr. Mark Ware, CAPRI trial primary investigator and
practicing pain physician at the McGill University Health Centre, and
Executive Director of the Canadian Consortium for the Investigation of
Cannabinoids (CCIC). "This research will help to start answering
important questions physicians have regarding dosing as well as short
term safety and efficacy related to specific ratios of cannabinoids."
The body's own pain-regulating system, called the endocannabinoid
system, has receptors in nervous system tissue, immune cells, bone and
joint tissue. These receptors respond to the cannabinoids found in
medical cannabis, similar to how a key opens a lock. Research has
demonstrated the short term efficacy of medical cannabis at reducing
pain when used by itself or in combination with other pain-relievers,
but comparisons between cannabinoid ratios have not been tested in
For the 4.6 million Canadians with arthritis, currently available
medications are often inadequate or associated with unacceptable side
effects. Research into new treatment options, including the potential
therapeutic benefit of medical cannabis, is an important next step in
determining options available to patients and their caregivers.
"We are very pleased to see that the CAPRI clinical trial is underway
and beginning recruitment," said Joanne Simons, chief mission officer,
The Arthritis Society. "We know that many people living with arthritis
seek alternative options for pain relief, including medical cannabis.
Well-designed clinical research is a pre-requisite to get us to where
we want to go: more treatment options available to help people manage
the pain of arthritis."
About CanniMed and Prairie Plant Systems
CanniMed Ltd. was the first producer to be licensed under the new Marihuana for Medical Purposes Regulations (MMPR). Our pharmaceutical-grade marijuana is produced under Good
Manufacturing Practices (GMP) regulations, the criteria used to
manufacture all pharmaceuticals in Canada. Our primary focus is on
patient safety, undertaken by strictly following a 281 point quality
CanniMed's parent company, Prairie Plant Systems Inc. was the sole supplier to Health Canada under the former medical
marijuana system for 13 years, and has been producing safe and
consistent medical marijuana for thousands of Canadian patients, with
no incident of diversion.
These two companies together have created the leading medical cannabis
company in Canada with a strong corporate priority to design and
execute clinical research that will close the gap between the anecdotal
benefit and evidence based medicine in order to standardize care. Our
Canadian-grown cannabis is already leading the way in standardizing
care and has been used in a published clinical trial demonstrating the
efficacy of smoked cannabis for chronic pain,i which was used in the development of the Canadian Pain Society's Pharmacological management of chronic neuropathic pain: Revised
consensus statement positioning medical cannabis as third line treatment for neuropathic
Note for editors:
Interview footage of Brent Zettl (Prairie Plant Systems/CanniMed) and
Joanne Simons (The Arthritis Society) are available, along with
manufacturing visuals, at the following coordinates: http://www.multivu.com/players/English/7558851-cnw-vod/
An audio news release featuring a quote with Brent Zettl (Prairie Plant
Systems/CanniMed) can be heard here: http://www.newscanada.com/mp3/ncradio4260.mp3 and is available for download at the following coordinates: http://www.newscanada.com/radio-new-segments#cat110.
i Ware, M.A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
ii Moulin, D.E., Boulanger, A., Clark A.J., Dao, T. and others. (2014)
Pharmacological Management of Chronic Neuropathic Pain: Revised
Consensus Statement from the Canadian Pain Society. Pain Research and Management. Nov-Dec; 19(6): 328-335.
SOURCE Prairie Plant Systems Inc.
Video with caption: "Video: B-roll - First Health Canada Approved Medical Cannabis Clinical Trial Starts Patient Recruitment ". Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20150623_C9771_VIDEO_EN_43662.mp4&posterurl=http://photos.newswire.ca/images/20150623_C9771_PHOTO_EN_43662.jpg&clientName=Prairie%20Plant%20Systems%20Inc%2E&caption=Video%3A%20B%2Droll%20%2D%20First%20Health%20Canada%20Approved%20Medical%20Cannabis%20Clinical%20Trial%20Starts%20Patient%20Recruitment%20&title=PRAIRIE%20PLANT%20SYSTEMS%20INC%2E%20%2D%20First%20Health%20Canada%20Approved%20Medical%20Cannabis%20Clinical%20Trial&headline=First%20Health%20Canada%20Approved%20Medical%20Cannabis%20Clinical%20Trial%20Starts%20Patient%20Recruitment
Image with caption: "Prairie Plant Systems Inc. (CNW Group/Prairie Plant Systems Inc.)". Image available at: http://photos.newswire.ca/images/download/20150623_C9771_PHOTO_EN_43657.jpg
Image with caption: "CanniMed Ltd. (CNW Group/Prairie Plant Systems Inc.)". Image available at: http://photos.newswire.ca/images/download/20150623_C9771_PHOTO_EN_43660.jpg
For further information:
Dara Willis Communications